Literature DB >> 9114205

beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.

J D Williams1.   

Abstract

beta-Lactamase inhibitors such as sulbactam are beta-lactam compounds that have low antimicrobial activity but are able to inhibit enzymes (beta-lactamases) that destroy beta-lactam antibiotics like penicillins and cephalosporins. The main activity of beta-lactamase inhibitors is directed against plasmid-mediated transferable enzymes and various extended-spectrum enzymes. Sulbactam is also active against some of the fixed chromosomally mediated enzymes produced by gram-negative bacteria and is active against Bacteroides and Acinetobacter species. Cefoperazone, a third-generation cephalosporin, is active against a wide range of gram-positive and gram-negative bacteria, including Enterobacteriaceae and Pseudomonas species. However, transferable beta-lactamases are now produced by numerous gram-negative organisms, mitigating the effectiveness of therapy with this agent. Chromosomally mediated enzymes are less common but can be induced in some strains of Klebsiella, Enterobacter, and Serratia species. The full potential of cefoperazone against Enterobacteriaceae and Pseudomonas species is restored by the addition of sulbactam; this addition extends cefoperazone's spectrum of activity to include Bacteroides and Acinetobacter species.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114205     DOI: 10.1093/clinids/24.3.494

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.

Authors:  Jien-Wei Liu; Yen-Hsu Chen; Wen-Sen Lee; Jung-Chung Lin; Ching-Tai Huang; Hsi-Hsun Lin; Yung-Ching Liu; Yin-Ching Chuang; Hung-Jen Tang; Yao-Shen Chen; Wen-Chien Ko; Min-Chi Lu; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Pharmacodynamics modeling to optimize dosage regimens of sulbactam.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Nanchanit Aeinlang; Monchana Jullangkoon
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  S Mohd Sazlly Lim; A J Heffernan; J A Roberts; F B Sime
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

Review 4.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Thitima Wattanavijitkul; Waroonrat Sukarnjanaset; Maseetoh Samaeng; Monchana Nawakitrangsan; Natnicha Ingviya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 7.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 8.  Host-pathogen interactions between the human innate immune system and Candida albicans-understanding and modeling defense and evasion strategies.

Authors:  Sybille Dühring; Sebastian Germerodt; Christine Skerka; Peter F Zipfel; Thomas Dandekar; Stefan Schuster
Journal:  Front Microbiol       Date:  2015-06-30       Impact factor: 5.640

9.  Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Ying-Chen Lu; Tsuey-Pin Lin; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Infect Drug Resist       Date:  2018-09-11       Impact factor: 4.003

Review 10.  Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors.

Authors:  Kayla R Stover; Katie E Barber; Jamie L Wagner
Journal:  Pharmacy (Basel)       Date:  2019-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.